Group items tagged

The Presidential Awards for Excellence in Science, Mathematics, and Engineering Mentoring (PAESMEM) is a Presidential award established by the White House in 1995. The purpose of the award is to recognize U.S. citizens or permanent residents and U.S. organizations that have demonstrated excellence in mentoring individuals from groups that are underrepresented in science, technology, engineering, and mathematics (STEM) education and workforce. Groups that are underrepresented in STEM include women, people with disabilities, underrepresented racial and ethnic minorities, as well as individuals from low socio-economic backgrounds and some geographic regions such as urban and rural areas. The PAESMEM program is administered by the National Science Foundation (NSF) on behalf of the White House Office of Science and Technology Policy (OSTP). Nominations, including self-nominations, are invited for Individual and Organizational PAESMEM awards. Individuals and organizations in all public and private sectors are eligible including industry, academia, primary and secondary education, military and government, non-profit organizations, and foundations. Nominations are encouraged from all geographical regions in the U.S., its territories or possessions, particularly jurisdictions designated by Congress under NSF's Experimental Program to Stimulate Competitive Research (EPSCoR).

The purpose of this Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative is to encourage applications that will develop and validate novel tools to facilitate the detailed analysis of complex circuits and provide insights into cellular interactions that underlie brain function. The new tools and technologies should inform and/or exploit cell-type and/or circuit-level specificity. Plans for validating the utility of the tool/technology will be an essential feature of a successful application. The development of new genetic and non-genetic tools for delivering genes, proteins and chemicals to cells of interest or approaches that are expected to target specific cell types and/or circuits in the nervous system with greater precision and sensitivity than currently established methods are encouraged. Tools that can be used in a number of species/model organisms rather than those restricted to a single species are highly desired. Applications that provide approaches that break through existing technical barriers to substantially improve current capabilities are highly encouraged.

The purpose of this Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative is to encourage applications that will develop and validate novel tools to facilitate the detailed analysis of complex circuits and provide insights into cellular interactions that underlie brain function. The new tools and technologies should inform and/or exploit cell-type and/or circuit-level specificity. Plans for validating the utility of the tool/technology will be an essential feature of a successful application. The development of new genetic and non-genetic tools for delivering genes, proteins and chemicals to cells of interest or approaches that are expected to target specific cell types and/or circuits in the nervous system with greater precision and sensitivity than currently established methods are encouraged. Tools that can be used in a number of species/model organisms rather than those restricted to a single species are highly desired. Applications that provide approaches that break through existing technical barriers to substantially improve current capabilities are highly encouraged.

The goal of this FOA is to advance research on the underlying basis for the transfer (or transposition) of aging phenotypes observed between young and old rodents and discovered through heterochronic parabiosis. Examples of transposed phenotypes include reversal of cardiac hypertrophy, partial restoration of cognitive function, improved vascularization, and repair of skeletal muscle after cryo-injury (anti-geronic transposition), or as accelerated loss of cognitive function and neurogenesis (pro-geronic transposition). Other transposed phenotypes, as revealed solely through heterochronic parabiosis, may also be reported in the literature. There are also reports of candidate factors found in circulation that might be causally related to the transposition of these aging phenotypes; these are termed "circulating geronic factors" for purposes of this FOA. To date, these are proteins and peptides that pass between the young and old mice joined by parabiosis, due to anastomosis of their circulatory systems. Based on these novel findings and this novel experimental paradigm, the specific objective of this FOA is to test whether these candidate geronic factors are necessary for the transposition of aging phenotypes. The focus is on phenotypes transposed in heterochronic parabiosis and the candidate factors which are present and functional at physiological concentrations in circulation.

The goal of this FOA is to advance research on the underlying basis for the transfer (or transposition) of aging phenotypes observed between young and old rodents and discovered through heterochronic parabiosis. Examples of transposed phenotypes include reversal of cardiac hypertrophy, partial restoration of cognitive function, improved vascularization, and repair of skeletal muscle after cryo-injury (anti-geronic transposition), or as accelerated loss of cognitive function and neurogenesis (pro-geronic transposition). Other transposed phenotypes, as revealed solely through heterochronic parabiosis, may also be reported in the literature. There are also reports of candidate factors found in circulation that might be causally related to the transposition of these aging phenotypes; these are termed "circulating geronic factors" for purposes of this FOA. To date, these are proteins and peptides that pass between the young and old mice joined by parabiosis, due to anastomosis of their circulatory systems. Based on these novel findings and this novel experimental paradigm, the specific objective of this FOA is to test whether these candidate geronic factors are necessary for the transposition of aging phenotypes. The focus is on phenotypes transposed in heterochronic parabiosis and the candidate factors which are present and functional at physiological concentrations in circulation.

Understanding the dynamic activity of neural circuits is central to the NIH BRAIN Initiative. Although invention and proof-of-concept testing of new technologies are a key component of the BRAIN Initiative, to achieve their potential these technologies must also be optimized through feedback from end-users in the context of the intended experimental use. This FOA seeks applications for the optimization of existing and emerging technologies and approaches that have potential to address major challenges associated with recording and manipulating neural activity, at or near cellular resolution, at multiple spatial and temporal scales, in any region and throughout the entire depth of the brain. This FOA is intended for the iterative refinement of emergent technologies and approaches that have already demonstrated their transformative potential through initial proof-of-concept testing, and are appropriate for accelerated development of hardware and software while scaling manufacturing techniques towards sustainable, broad dissemination and user-friendly incorporation into regular neuroscience practice. Proposed technologies should be compatible with experiments in behaving animals, and should include advancements that enable or reduce major barriers to hypothesis-driven experiments. Technologies may engage diverse types of signaling beyond neuronal electrical activity for large-scale analysis, and may utilize any modality such as optical, electrical, magnetic, acoustic or genetic recording/manipulation. Applications that seek to integrate multiple approaches are encouraged. Applications are expected to integrate appropriate domains of expertise, including where appropriate biological, chemical and physical sciences, engineering, computational modeling and statistical analysis. Also listed under R01

The mission of the Biomedical Engineering (BME) program is to provide opportunities to develop novel ideas into discovery-level and transformative projects that integrate engineering and life science principles in solving biomedical problems that serve humanity in the long-term.  The Biomedical Engineering (BME) program supports fundamental research in the following BME themes: Neural engineering (brain science, computational neuroscience, brain-computer interface, neurotech, cognitive engineering) Cellular biomechanics (motion, deformation, and forces in biological systems; how mechanical forces alter cell growth, differentiation, movement, signal transduction, transport, cell adhesion, cell cytoskeleton dynamics, cell-cell and cell-ECM interactions; genetically engineered stem cell differentiation with long-term impact in tissue repair and regenerative medicine) The BME projects must be at the interface of engineering and life sciences, and advance both engineering and life sciences.  The projects should focus on high impact transforming methods and technologies. The project should include methods, models and tools of understanding and controlling of living systems; fundamental improvements in deriving information from cells, tissues, organs, and organ systems; new approaches to the design of structures and materials for eventual medical use in the long-term; and new novel methods of reducing health care costs through new technologies.

The purpose of this Funding Opportunity Announcement (FOA) is to invite applications proposing the innovative analysis of existing social science, behavioral, administrative, and neuroimaging data to study the etiology and epidemiology of drug using behaviors (defined as alcohol, tobacco, prescription and other drug) and related disorders, prevention of drug use and HIV, and health service utilization. This FOA encourages the analyses of public use and other extant community-based or clinical datasets to their full potential in order to increase our knowledge of etiology, trajectories of drug using behaviors and their consequences including morbidity and mortality, risk and resilience in the development of psychopathology, strategies to guide the development, testing, implementation, and delivery of high quality, effective and efficient services for the prevention and treatment of drug abuse and HIV.

The purpose of this Funding Opportunity Announcement (FOA) is to invite applications proposing the innovative analysis of existing social science, behavioral, administrative, and neuroimaging data to study the etiology and epidemiology of drug using behaviors (defined as alcohol, tobacco, prescription and other drug) and related disorders, prevention of drug use and HIV, and health service utilization. This FOA encourages the analyses of public use and other extant community-based or clinical datasets to their full potential in order to increase our knowledge of etiology, trajectories of drug using behaviors and their consequences including morbidity and mortality, risk and resilience in the development of psychopathology, strategies to guide the development, testing, implementation, and delivery of high quality, effective and efficient services for the prevention and treatment of drug abuse and HIV.

With PEPFAR support, CDC Haiti works in close collaboration with Haiti’s Ministry of Health (MSPP) to increase access to quality HIV clinical services, prevent mother-to-child transmission of HIV, and increase laboratory and strategic information capacity. In 2016, CDC Haiti adopted and implemented WHO’s Test and Start strategy, making treatment available to anyone who is HIV positive and reaching 80,000 people – over half of all people living with HIV in Haiti. The CDC program also led the development and implementation of key innovative approaches such as the biometric coding for unique patient identification and patient linkage and retention program. These interventions significantly improved the PEPFAR Haiti program performance. This NOFO aims to build upon these interventions and improve:Service delivery by providing technical assistance in the MSPP network to help strengthen HIV/AIDS-related services through clinical mentoring;Health workforce development by supporting both pre-service and in-service training efforts and working with MSPP in maintaining its national clinical guidelines; andHealth information systems by enhancing the iSanté Plus system, which includes patient care summaries, population-level data dashboards, automated program reports, epidemiological monitoring, and indicator reporting, and is linked to computerized lab results.

Alzheimer's disease (AD) is a progressive, degenerative disorder of the brain and is the most common form of dementia of the elderly. AD is the sixth leading cause of death in the United States. Prominent behavioral manifestations of AD include memory impairments and decline in other cognitive domains.  Currently, at least five million Americans at age 65 and older suffer from AD, and it is projected that the number of new cases of AD will double by 2025. AD is clearly becoming a national health crisis affecting Americans across the country, and the total annual payments of health care for people with AD are projected to be more than $1 trillion in 2050. In response to this looming public health crisis, the National Alzheimer's Project Act (NAPA) was signed into law in 2011. The primary research goal of the NAPA is to prevent the onset of, and develop effective treatments for, AD by 2025. As part of the strategic planning process to implement NAPA, NIH AD Research Summits were held in 2012 and 2015 and identified research priorities and strategies needed to accelerate basic research and the development of effective therapies. A FY2017 Alzheimer's disease bypass budget with milestones was published in 2015 to establish research and funding priorities in response to the NAPA and the AD Research Summits (https://www.nia.nih.gov/alzheimers/bypass-budget-fy2017). This funding opportunity announcement was developed in response to the recommendations of the AD Research Summits and milestones published in the FY2017 Alzheimer's disease bypass budget to support interdisciplinary research to understand the heterogeneity and multifactorial etiology of AD. 

Alzheimer's disease (AD) is a progressive, degenerative disorder of the brain and is the most common form of dementia of the elderly. AD is the sixth leading cause of death in the United States. Prominent behavioral manifestations of AD include memory impairments and decline in other cognitive domains. Currently, at least five million Americans at age 65 and older suffer from AD, and it is projected that the number of new cases of AD will double by 2025. AD is clearly becoming a national health crisis affecting Americans across all regions of the country, and the total annual payments of health care for people with AD are projected to be more than $1 trillion in 2050. In response to this looming public health crisis, the National Alzheimer's Project Act (NAPA) was signed into law in 2011. The primary research goal of the NAPA is to prevent the onset of and develop effective treatments for AD by 2025.  As part of the strategic planning process to implement NAPA, NIH AD Research Summits were held in 2012 and 2015 and identified research priorities and strategies needed to accelerate basic research and the development of effective therapies. A FY2017 Alzheimer's disease bypass budget with milestones was published in 2015 to establish research and funding priorities in response to the NAPA and the AD Research Summits (https://www.nia.nih.gov/alzheimers/bypass-budget-FY 2017). This funding opportunity announcement was developed in response to the recommendations of the AD Research Summits to support interdisciplinary research to understand the heterogeneity and multifactorial etiology of AD.

This funding opportunity announcement (FOA) spans across the missions of several NIH Institutes and Centers (ICs) and Offices, and includes basic neuroscience and basic behavioral research, clinical and translational studies, intervention development at the individual, family and community level, efficacy trials of interventions based on evidence from basic and translational studies, and research to identify the best ways to disseminate and implement efficacious and evidence-based interventions in real-world settings. While this FOA covers all of the areas mentioned above, particular consideration will be given to applications that propose studies of the intersection that focus on the various types of violence (homicide, suicide, youth and gang-related, intimate partner) and firearms.

This funding opportunity announcement (FOA) spans across the missions of several NIH Institutes and Centers (ICs) and Offices, and includes basic neuroscience and basic behavioral research, clinical and translational studies, intervention development at the individual, family and community level, efficacy trials of interventions based on evidence from basic and translational studies, and research to identify the best ways to disseminate and implement efficacious and evidence-based interventions in real-world settings. While this FOA covers all of the areas mentioned above, particular consideration will be given to applications that propose studies of the intersection that focus on the various types of violence (homicide, suicide, youth and gang-related, intimate partner) and firearms.

This funding opportunity announcement (FOA) spans across the missions of several NIH Institutes and Centers (ICs) and Offices, and includes basic neuroscience and basic behavioral research, clinical and translational studies, intervention development at the individual, family and community level, efficacy trials of interventions based on evidence from basic and translational studies, and research to identify the best ways to disseminate and implement efficacious and evidence-based interventions in real-world settings. While this FOA covers all of the areas mentioned above, particular consideration will be given to applications that propose studies of the intersection that focus on the various types of violence (homicide, suicide, youth and gang-related, intimate partner) and firearms.

A central goal of the BRAIN Initiative is to understand how electrical and chemical signals code information in neural circuits and give rise to sensations, thoughts, emotions and actions. Available technologies for recording and manipulating neural circuit activity in human and animal experiments are not sufficient to accomplish this goal. Non-invasive technologies are low resolution and/or provide indirect measures such as blood flow, which are imprecise. Invasive technologies can provide information at the level of single neurons producing the fundamental biophysical signals, but they can only be applied to tens or hundreds of neurons, out of a total number in the human brain estimated at 85 billion. Previous BRAIN FOAs sought to develop novel technology (RFA-NS-15-003) or to optimize existing technology ready for in-vivo proof-of-concept testing and collection of preliminary data (RFA-NS-15-004). This FOA seeks applications for technology at an even earlier stage of development. It seeks new and untested ideas that are in the very earliest stages. The support provided might enable calculations, simulations, computational models, or other mathematical approaches for demonstrating that the signal sources and/or measurement technologies are theoretically capable of meeting the demands of large-scale recording or manipulation of circuit activity. The support might also be used for building and testing phantoms, prototypes, in-vitro or other bench-top models in order to validate underlying theoretical assumptions in preparation for future FOAs aimed at testing in animal models. Invasive or non-invasive approaches are sought that will ultimately enable or reduce the current barriers to large-scale recording or manipulation of neural activity, and that would be compatible with experiments in humans or behaving animals. Applications are encouraged from any qualified individuals, including physicists, engineers, theoreticians, and scientists, especially those no

The NIH Blueprint for Neuroscience Research is a collaborative framework through which 14 NIH Institutes, Centers and Offices jointly support neuroscience-related research, with the aim of accelerating discoveries and reducing the burden of nervous system disorders. This Funding Opportunity Announcement (FOA) will solicit research projects to facilitate the development and translation of tools and technology for non-invasive imaging and profiling of human central nervous system (CNS, including retina) small blood and lymphatic vessels; to investigate their role in CNS physiology, disease, repair processes, and responses to therapy using novel approaches. Applications can be focused on the development of new technology and tools, novel target or biomarker identification and validation studies, or a combination of mechanistic and technology development studies specific to human CNS small blood and lymphatic vessels in health and disease, across the life span.

The purpose of NIDILRR's Disability and Rehabilitation Research Projects (DRRP), which are funded through the Disability and Rehabilitation Research Projects and Centers Program, is to plan and conduct research and dissemination and utilization activities to develop methods, procedures, and rehabilitation technology that maximize the full inclusion and integration into society, employment, independent living, family support, and economic and social self-sufficiency of individuals with disabilities, especially individuals with the most severe disabilities, and to improve the effectiveness of services authorized under the Rehabilitation Act of 1973, as amended (Rehabilitation Act). The purpose of this particular DRRP is to generate new knowledge about the effectiveness of interventions to improve college education and employment outcomes of people with serious mental illness or traumatic brain injury.

The purpose of this FOA is to promote the integration of experimental, analytic, and theoretical capabilities for large-scale analysis of neural systems and circuits. This FOA seeks applications for exploratory research studies that use new and emerging methods for large scale recording and manipulation of neural circuits across multiple brain regions. Applications should propose to elucidate the contributions of dynamic circuit activity to a specific behavioral or neural system. Applications should seek to understand circuits of the central nervous system by systematically controlling stimuli and/or behavior while actively recording and/or manipulating relevant dynamic patterns of neural activity and by measuring the resulting behaviors and/or perceptions. Studies should incorporate rich information on cell-types, on circuit functionality and connectivity, and should be performed in conjunction with sophisticated analysis of complex, ethologically relevant behaviors. Applications should propose teams of investigators that seek to cross boundaries of interdisciplinary collaboration by bridging fields and linking theory and data analysis to experimental design. Exploratory studies supported by this FOA are intended to develop experimental capabilities and quantitative, theoretical frameworks in preparation for a future competition for larger-scale, multi-component, Team-Research BRAIN Circuit Programs (U19).

This initiative will foster collaborative and coordinated efforts to characterize the underlying genetic architecture of diverse neuropsychiatric phenotypes within and across rare genetic disorders and identify the shared genetic risk across rare and idiopathic neuropsychiatric disorders. Projects from multi-disciplinary teams will utilize genome-wide data to comprehensively assess the contribution of genetic variation to the variable expressivity and incomplete penetrance of neuropsychiatric phenotypes across rare genetic disorders. Projects are encouraged to leverage existing resources, cohorts, and collaborative networks with established infrastructure for consistent and high-quality phenotypic data collection and genomic data generation. Projects should seek to enhance the quality of the phenotypic data available for rare genetic disorders by developing or applying phenotyping methodologies that create a pipeline for standardizing assessments and that cut across rare genetic disorders and across developmental time points. Under this initiative, investigators will form a network to facilitate data sharing and harmonization of clinical and genetic data across different studies within the network, as well as accelerate characterization of genotype to phenotype relationships across rare genetic disorders. This network will also generate a resource of bio-samples, as well as phenotypic and genetic data for broader dissemination to the scientific community.

The goal of this FOA is to support short courses geared to behavioral and social scientists who have existing expertise in aging research and can make research contributions in Alzheimer's disease and Alzheimer's disease-related dementias (AD/ADRD) with additional knowledge about the disease and related research resources. Fields of behavioral and social science research relevant for this FOA are health economics, labor economics, health services research, healthcare policy, public policy, demography, sociology, social epidemiology, psychology, and social neuroscience. Priority areas of focus include, but are not limited to, the following: dementia care; dementia caregiver research; cognitive and dementia epidemiology; behavioral and social pathways of AD/ADRD; role of social, contextual, environmental, and institutional factors in AD/ADRD; early psychological changes preceding AD/ADRD onset; prevention of AD/ADRD; disparities in AD/ADRD or dementia-related outcomes; and research resources and methods for studying the determinants and impact of AD/ADRD.

NIFA requests applications for the Mental Health Research Project (MHRP) for the fiscal year FY 2017 to support the Air Force Medical Operations Agency (AFMOA) MHRP in promoting the psychological health and well being for Airmen and there families through staff development, consultation, program and resource development; program evaluation, and data tracking.The primary objective for this project is to assess, develop, and evaluate programming to treat and prevent mental health problems to support the Mental Health Division of the Air Force Medical Operations Agency (AFMOA).This work also supports the mission of the DoD-USDA Partnership for Military Families Memorandum of Understanding (MOU) signed in 2010 by NIFA and DoD senior leadership. The goal of the MOU is "…to enhance federal interagency coordination and build capacity for partnerships and collaboration among the agencies and across public and private sectors to sustain programs and services for military service members and their families."